CN106928218B - 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途 - Google Patents

吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途 Download PDF

Info

Publication number
CN106928218B
CN106928218B CN201611246909.0A CN201611246909A CN106928218B CN 106928218 B CN106928218 B CN 106928218B CN 201611246909 A CN201611246909 A CN 201611246909A CN 106928218 B CN106928218 B CN 106928218B
Authority
CN
China
Prior art keywords
morpholine derivative
degrees
morpholine
tartrate
malate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201611246909.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN106928218A (zh
Inventor
夏广新
谢建树
贾国慧
韩建生
上田直子
饭嶋彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Pharmaceuticals Holding Co Ltd
Original Assignee
Shanghai Pharmaceuticals Holding Co Ltd
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Pharmaceuticals Holding Co Ltd, Mitsubishi Tanabe Pharma Corp filed Critical Shanghai Pharmaceuticals Holding Co Ltd
Priority to CN202110801274.0A priority Critical patent/CN113816952A/zh
Priority to CN202110794158.0A priority patent/CN113816951B/zh
Publication of CN106928218A publication Critical patent/CN106928218A/zh
Application granted granted Critical
Publication of CN106928218B publication Critical patent/CN106928218B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201611246909.0A 2015-12-29 2016-12-29 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途 Active CN106928218B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110801274.0A CN113816952A (zh) 2015-12-29 2016-12-29 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途
CN202110794158.0A CN113816951B (zh) 2015-12-29 2016-12-29 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015110167833 2015-12-29
CN201511016783 2015-12-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202110801274.0A Division CN113816952A (zh) 2015-12-29 2016-12-29 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途
CN202110794158.0A Division CN113816951B (zh) 2015-12-29 2016-12-29 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途

Publications (2)

Publication Number Publication Date
CN106928218A CN106928218A (zh) 2017-07-07
CN106928218B true CN106928218B (zh) 2021-08-03

Family

ID=59224612

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201611246909.0A Active CN106928218B (zh) 2015-12-29 2016-12-29 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途
CN202110801274.0A Pending CN113816952A (zh) 2015-12-29 2016-12-29 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途
CN202110794158.0A Active CN113816951B (zh) 2015-12-29 2016-12-29 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110801274.0A Pending CN113816952A (zh) 2015-12-29 2016-12-29 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途
CN202110794158.0A Active CN113816951B (zh) 2015-12-29 2016-12-29 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途

Country Status (11)

Country Link
US (1) US10519150B2 (enExample)
EP (1) EP3398946B1 (enExample)
JP (1) JP6818031B2 (enExample)
CN (3) CN106928218B (enExample)
DK (1) DK3398946T3 (enExample)
ES (1) ES2918674T3 (enExample)
HU (1) HUE059444T2 (enExample)
PL (1) PL3398946T3 (enExample)
PT (1) PT3398946T (enExample)
TW (1) TWI705065B (enExample)
WO (1) WO2017114456A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022047730A1 (en) 2020-09-04 2022-03-10 Shanghai Pharmaceuticals Holding Co., Ltd. Methods to treat inflammatory bowel disease
JP7579967B2 (ja) * 2020-09-04 2024-11-08 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 窒素含有飽和複素環化合物の使用
CN116425677A (zh) * 2022-01-11 2023-07-14 苏州恩华生物医药科技有限公司 氨基环丁烷衍生物的盐、其晶型及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103562191A (zh) * 2011-03-16 2014-02-05 上海医药集团股份有限公司 含氮的饱和杂环化合物
WO2014042263A1 (ja) * 2012-09-14 2014-03-20 田辺三菱製薬株式会社 新規レニン阻害薬

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
JP5764628B2 (ja) * 2012-09-14 2015-08-19 田辺三菱製薬株式会社 医薬組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103562191A (zh) * 2011-03-16 2014-02-05 上海医药集团股份有限公司 含氮的饱和杂环化合物
WO2014042263A1 (ja) * 2012-09-14 2014-03-20 田辺三菱製薬株式会社 新規レニン阻害薬

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pharmaceutical Salts;Stephen M. Berge et al.;《Journal of Pharmaceutical Sciences》;19770131;第66卷(第1期);第1-19页 *

Also Published As

Publication number Publication date
CN113816951B (zh) 2022-09-27
EP3398946A4 (en) 2019-08-28
PT3398946T (pt) 2022-08-09
CN113816951A (zh) 2021-12-21
EP3398946B1 (en) 2022-05-04
US10519150B2 (en) 2019-12-31
JP6818031B2 (ja) 2021-01-20
PL3398946T3 (pl) 2022-10-10
CN106928218A (zh) 2017-07-07
TW201722950A (zh) 2017-07-01
WO2017114456A1 (zh) 2017-07-06
JP2019500385A (ja) 2019-01-10
ES2918674T3 (es) 2022-07-19
TWI705065B (zh) 2020-09-21
DK3398946T3 (da) 2022-08-08
CN113816952A (zh) 2021-12-21
US20190016718A1 (en) 2019-01-17
HUE059444T2 (hu) 2022-11-28
EP3398946A1 (en) 2018-11-07

Similar Documents

Publication Publication Date Title
TWI624447B (zh) 吡咯衍生物的結晶及其製造方法
AU2015330554B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
WO2017008773A1 (en) Crystalline forms of obeticholic acid
JP2015522037A (ja) ベムラフェニブコリン塩の固体形態
CN106928218B (zh) 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途
US20150150868A1 (en) Aripiprazole-organic acid cocrystal, preparation or composition containing same, and preparation method therefor
KR100878698B1 (ko) 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및이를 포함하는 약학 조성물
US12384784B2 (en) Polymorphs of Acalabrutinib, a Bruton's tyrosine kinase inhibitor
JP7152122B2 (ja) エダラボン塩
WO2023137966A1 (zh) 一种徳拉沙星葡甲胺盐新晶型及其制备方法
WO2015170340A2 (en) Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof
JP6871255B2 (ja) ゲフィチニブの結晶形ａを製造する方法
KR102355955B1 (ko) 퀴나졸린 유도체의 염, 이의 제조 방법 및 응용
WO2013007519A1 (en) Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
KR101307712B1 (ko) 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및 이를 포함하는 약학 조성물
WO2025167588A1 (zh) Zipalertinib的晶型及其制备方法和用途
WO2025232904A1 (zh) 替戈拉生富马酸单乙酯、其制备方法、药物组合物及应用
WO2017035170A1 (en) Solid state forms of cediranib maleate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20250620

Address after: 201203 Pudong New Area Zhangjiang Road, Shanghai, No. 92

Patentee after: SHANGHAI PHARMACEUTICALS HOLDING Co.,Ltd.

Country or region after: China

Address before: 201203 Pudong New Area Zhangjiang Road, Shanghai, No. 92

Patentee before: SHANGHAI PHARMACEUTICALS HOLDING Co.,Ltd.

Country or region before: China

Patentee before: MITSUBISHI TANABE PHARMA Corp.

Country or region before: Japan

TR01 Transfer of patent right